Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health (Nasdaq: GH) announced positive results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy (PICI). The study evaluated Guardant Reveal, a tissue-free monitoring tool for detecting immunotherapy responses in advanced cancer patients.
The research, published in Cancer Research Communications, analyzed over 500 patients with various advanced solid tumors. Key findings showed that Guardant Reveal could identify non-responders up to 5 months earlier than standard methods. Patients with ≥80% decrease in tumor fraction showed a 75% lower risk of progression. The study covered multiple cancer types, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers.
Guardant Health (Nasdaq: GH) announced the enrollment of the first patient in the National Cancer Institute's Vanguard Study, which will evaluate the company's Shield Multi-Cancer Detection (MCD) test. The four-year study aims to enroll up to 24,000 participants aged 45-75 who are cancer-free.
The Shield MCD test, which recently received FDA Breakthrough Device Designation, can screen for 10 different cancer types through a simple blood draw. The test was selected based on its performance in detecting lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric cancers. The study's results will inform the design of a larger randomized controlled trial for cancer screening evaluation.
Guardant Health (NASDAQ: GH), a precision oncology company, has scheduled its Q2 2025 earnings release for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day.
The earnings webcast will be accessible through the Investors section of Guardant Health's website, with a replay available after the event.